$20.28 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2023 (TTM): $2.20 B

According to BeiGene 's latest financial reports the company's current revenue (TTM) is $2.20 B. In 2022 the company made a revenue of $1.41 B an increase over the years 2021 revenue that were of $1.17 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2023

Annual revenue

Year Revenue Change
2023 (TTM)$2.20 B55.69%
2022$1.41 B20.37%
2021$1.17 B280.83%
2020$0.30 B-27.87%
2019$0.42 B116.03%
2018$0.19 B-16.85%
2017$0.23 B22179.16%
2016$1.07 M-87.86%
2015$8.81 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
$0.86 B-60.67%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.22 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA